Objective To investigate the efficacy and safety of sertraline combining with risperidone in the treatment of obsessive-compulsive disorder (OCD). Methods A total of 88 patients who met the criteria for OCD in International Classification of Diseases (ICD-10) were randomly assigned to two groups. One group was treated with sertraline combining with risperidone and the other with sertraline only for 8 weeks. The efficacy was measured with the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and the Hamilton Depression Scale (HAMD). The side effects were assessed with the Treatment Emergent Symptoms Scale (TESS). Results At end point the significant improvement rate in the combining group was higher than that in the sertraline group (68.2% vs 43.2%, P<0.05). In combining group, the YBOCS score [(12.75±4.39) vs (14.47±4.09), P<0.001] and HAMD score [(6.79±2.53) vs (8.319±3.12), P<0.001] were decreased after treatment. In sertraline group, the YBOCS score [ (14.47±4.09) vs (12.75±4.39), P=0.011] was also decreased after treatment. There were significant differences between the two groups (P<0.05). There were no significant differences between the two groups in the TESS score at the end of 2, 4, 6 and 8 weeks (P>0.05). Conclusion The addition of risperidone to sertraline therapy has been found to be effective and well-tolerated approach in patients with OCD.
AIM To evaluate the efficacy and safety of bupropion for smoking cessation in schizophrenia.METHODS A randomized and double-blind controlled clinical trial was conducted for smoking cessation.The experimental group(n = 36) treated with bupropion tablet 150 ～ 300 mg·d-1 and the control group(n = 33) with placebo were carried out for 4 weeks and observed for 8 weeks.Efficacy and adverse reactions were assessed by cessation diary, the score of tobacco dependence, withdrawal rate, TESS, laboratory examination, respectively;and the changes of psychiatric symptoms.was evaluated by BPRS Statistical with SPSS13.0 software was used for data processing with t test, nonparametric test and χ2 test for efficacy analysis.RESULTS A total of 69 male schizophrenia in hospital showed the decrement of cigarettes use per day more significantly in the experimental group than that in the control group(P 0.01) after 1 week of the treatment.The efficacy rates at the end of 4th and 8th week of the experimental group were 33.3% and 27.8% respectively, showing significant difference with the control group(9.1% and 6.1%, respectively)(P 0.01) .The common adverse reactions of the experimental group were insomnia, dry mouth, restlessness, headache, nausea, and diaphoresis, etc, showing higher incidences and significant difference with the control group(P 0.05) .CONCLUSION Bupropion with mild adverse reactions and well toleration is effective and safe for smoking cessation in patients with schizophrenia.
<span id="ChDivSummary" name="ChDivSummary" class="abstract-text">目的:了解基层医务工作者的职业倦怠和社会支持现状,为提高基层卫生人力资源管理效率提供依据。方法:采用整群抽样方法,用Maslach职业倦怠量表（MBI）和社会支持评定量表（SSRS）对91名基层医生进行调查。结果:工作10年以上组职业倦怠与10年以下组无显著性差异,社会支持得分显著高于工作10年以下组（P<0.05）。基层精神病科医生和同级别综合医院的医生比较在职业枯竭方面的得分要低而社会支持的得分要高一些,但没有显著的统计学意义（P>0.05）。已婚组职业枯竭和社会支持的得分高于未婚组,但无显著差异。对本职工作兴趣浓厚组在情感衰竭和去人性化方面得分要显著低于兴趣一般组（P<0.05）,而在客观支持方面的得分要高于兴趣一般组。职业倦怠的去人性化因子与社会支持成负相关关系,而成就感则与社会支持成正相关。结论:基层高年资医师在享受更多社会支持的同时面临着更大的职业压力。基层医务工作者中精神科医师与其他科室医师之间职业倦怠和社会支持无统计学差异性。良好的社会支持和浓厚的专业兴趣是有效对抗职业倦怠的武器。</span>
Objective To explore the efficacy and side effects of modified electroeonvulsive therapy (MECT) in treatment of refractory obsessive compulsive disorder. Methods A total of 79 patients with refractory obsessive compulsive disorder were randomly divided into study group with MECT and control group with antide-pressants for treatment of 4 weeks. They were assessed and analysed eontrastively using Yale-Brown Obsessive Compulsive Scale (YBOCS), Hamilton Axiety Scale (HAMA) and Treatment Emergent Side Effect Scale (TESS). Results In the 1st weekend,the total scores of YBOCS (22.47±3.09)and HAMA (19.59±3.51)in study group were significantly decreased than those before treatment(as follows: 27.07±1.34,24.99±3.76)( t =6.10～7.69, P<0.05) and there was no difference in control group(t= 1.32～1.78, P0.05). In the lst,2nd and 4th weekend, the total scores of YBOCS (as follows : 22.47±3.09,14.93±2.92,10.93±4.23) and HAMA (as follows: 19.59±3.51,16.60±2.97,11.40±2.68) in study group were significantly lower than the total scores of YBOCS (as follows: 26.33±4.49,21.40±3.58,19.60±4.26) and HAMA (as follows: 24.38± 3.34,20.78±4.05, 19.79±3.08) in control group(t=4.36±21.30, P < 0.05). In the 1st,2nd and 4th weekend,the effective rates had significant differencesn between study group (as follows: 35.90,58.97,74.36%) and control group(as follows : 0.00%, 17.50,32.50%) (X2= 13.90～14.42, P < 0.05). No severe side effect was found in study group. Conclusion MECT is effective in treating refractory obsessive compulsive disorder without severe side effects.
Objective To explore the efficacy and side effects of modified electroconvulsive therapy (MECT) in the treatment of catatonic schizophrenia. Methods A total of 81 patients with catatonic schizophrenia were randomly divided into study group with MECT and control group with risperidone for treatment of 4 weeks. They were assessed and analysed contrastively using Brief Psychiatrc Rating Scale (BPRS) , Nurses Observation Scale (NOSIE) and Treatment Emergent Side Effect Scale (TESS) . Results In the 1st weekend, the total and factor scores of BPRS and NOSIE in study group were significantly lower than before treatment(P0.05) and there was no difference in control group(P0.05). In the 4th weekend, there were significant improvement of BPRS and NOSIE both in study group and control group(P0.05). But the total and factors scores of BPRS and NOSIE had significant differences between study group and control group(P0.05). No severe side effects was found in study group. Conclusion MECT is effective for treating patients with catatonic schizophrenia without severe side effects.
Objective To investigate serum levels of homocysteine in inpatients with major depressive disorder and relationship between serum homocysteine levels and depressive symptoms.Methods A total of 40 patients with major depressive disorder in study group and 36 normal health controls in control group were collected in this study.The serum levels of homocysteine were determined by Fluorescence Polarization Immunoassay(FPIA).The 17-item Hamilton Rating Scale for Depression(HAMD) was used to evaluate depressive symptoms.Results In study group,the serum homocysteine level was not significantly related to sex,treatment,family history,age and duration of depression(P0.05).The serum homocysteine level was significantly higher in study group than that in control group[(16.45±5.96)μmol/L,(11.72±3.33)μmol/L;P0.05].The rate of Hyperhomocysteinemia(HHcy) in study group was significantly higher than that in control group[(42.50)%,(10.00)%,P0.05].In study group,the score of HAMD was significantly positively related to serum homocysteine level(r=0.724,P0.05).The score of HAMD in patients with HHcy was significantly higher than that in patients without HHcy(t=5.209,P0.05).Conclusion The increase of serum homocysteine levels maybe play an important risk factor in the pathogenic mechanism of depressive disorder,and the serum homocysteine level could influence severity of depression.
